Autologous Plasma Rich in Growth Factors Eyedrops in Refractory Cases of Ocular Surface Disorders

Merayo‐Lloves, Jesús; Sanchez, Ronald M; Riestra, Ana Cristina; Anitua, Eduardo; Begoña, Leire; Orive, Gorka; Fernández-Vega, Luís

doi:10.1159/000439280

Cited by 48 publications

(25 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, a statistically signi cant decrease (p < 0.01) was observed in different variables measured such as the percentage of the corneal defect, corneal staining area, corneal staining density, VAS frequency, VAS severity, degree of dry eye disease and OSDI. Similar results were found in previous publications where the use of PRGF alone improved the values of discomfort in patients with ocular surface disorders 1,20 . These successful results could be in part due to the PRGF characteristics like its analgesic or anti-in ammatory effect, which has been widely demonstrated in the previous studies 24 .…”

Section: Discussionsupporting

confidence: 91%

“…The ocular surface involves structures like the cornea, limbus and conjunctiva, which protect the ocular integrity against external pathogens under normal conditions 1 . However, there are noninfectious disorders that can generate lesions with a variable severity grade from super cial keratitis to ulcers and corneal melting, which can permanently affect the visual acuity in many cases 2 .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

Sánchez-Ávila

Uribe-Badillo²,

Gonzalez³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: To provide the efficacy and safety of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers.Methods: This retrospective study included patients from Fernandez-Vega University Institute between 2010 and 2019, with noninfectious corneal ulcers and no response to standard treatments. RGTA treatment was firstly applied (1 drop every two days), but if ulcer closure was not achieved, PRGF eye drops treatment was added (4 times/day). The time to reach the ulcer closure; the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. The presence of adverse events along the follow-up period was also reported. Results: Seventy-four patients (79 eyes) were included in the study, forty-six eyes (62.2%) were women, and the mean age was 56.8 ± 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder found in the patients of the study (n = 27, 34.2%), mainly due to the herpes virus (n = 15, 19.0%). The mean time of PRGF eye drops treatment associated with RGTA matrix was 4.2 ± 2.2 (1.5 -9.0) months, and the follow-up period was 44.9 ± 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved significantly from the baseline (p<0.001), while IOP remained unchanged (p=0.665). No adverse events were recorded. Conclusions: The use of RGTA and PRGF in noninfectious ulcers was effective and safe, and it could be a therapeutic alternative for this type of corneal diseases.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

Sánchez-Ávila

Uribe-Badillo²,

Gonzalez³

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“… 17 A better control on inflammation could contribute to a higher treatment adherence in patients with glaucoma. Last but not least, PRGF eye drops have shown clinical efficacy in patients with moderate-to-severe dry eye, diverse epithelial defects, and corneal ulcers; 18 , 19 , 10 , 28 – 30 the efficacy and safety of PRGF eye drops in the treatment of neurotrophic keratitis have also been demonstrated. 31 …”

Section: Discussionmentioning

confidence: 99%

Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma

Sánchez-Ávila¹,

Merayo‐Lloves²,

Fernández³

et al. 2018

IMCRJ

Self Cite

View full text Add to dashboard Cite

PurposeTo evaluate the efficacy and safety of plasma rich in growth factors (PRGF) eye drops in patients with glaucoma with secondary ocular surface disorders (OSDs) due to surgeries and topical hypotensive drugs use.Materials and methodsA retrospective case-series study design was used including six patients (eight eyes) diagnosed with glaucoma who received surgical (nonpenetrating deep sclerectomy and/or trabeculectomy) and medical treatments (hypotensive eye drops) to control intraocular pressure (IOP) and who developed secondary OSDs, unresponsive to conventional treatments. Patients were treated with PRGF eye drops (four times a day). Outcome measures were ocular surface disease index (OSDI), best-corrected visual acuity (BCVA, in logarithm of the minimum angle of resolution), visual analog scale (VAS), frequency and severity of symptoms, and IOP. The safety of the treatment was also evaluated.ResultsSix patients (seven eyes with open-angle glaucoma and one eye with uveitic glaucoma) treated with PRGF eye drops were evaluated. Mean age was 71 years (SD=7.2, range 58–79 years). Five were female and one was male. The mean treatment time was 21.8 weeks (SD=9.0, range 12–36 weeks). The mean time to reach closure of the corneal ulcer was 14.5 (SD=5.5) weeks. A statistical significant reduction in OSDI scale (50.6%), VAS frequency (53.1%), VAS severity (42.0%), and a 41.8% improvement in BCVA were observed (p<0.05). IOP also decreased by 16.6% (p=0.010). Only one of the six patients reported itching in both eyes as an adverse event (AE); however, the patient continued with the PRGF eye drops until the end of therapy; the remaining patients did not report any AEs during the follow-up period.ConclusionsIn patients with glaucoma and secondary OSDs refractive to conventional treatments, the treatment with PRGF eye drops could be considered a possible therapeutic option, because it demonstrates an improvement in the signs and symptoms of the ocular surface, as well as a better control of the IOP. This is an initial research work that can open doors for future research to confirm these findings.

show abstract

“…[8][9][10] In recent years, PRGF eye drops have been widely used in the treatment of several ocular surface diseases, including dry eye, corneal ulcers, and persistent epithelial defects. [11][12][13][14][15][16][17][18] The biochemical and biophysical properties of PRGF eye drops like pH, osmolarity, proteins, and growth factors content, which are similar to the artificial tears, are responsible for the successful results obtained in the treatment of these different ocular pathologies. 19,20 Ocular surface disorders are usually chronic diseases that require medium-or long-term treatment.…”

Section: Introductionmentioning

confidence: 99%

Development and Optimization of Freeze-Dried Eye Drops Derived From Plasma Rich in Growth Factors Technology

Anitua

Fuente

Alcalde

et al. 2020

Trans. Vis. Sci. Tech.

Self Cite

View full text Add to dashboard Cite

To investigate whether plasma rich in growth factors (PRGF) eye drops maintain their biological potential after a freeze drying process. The addition of a lyoprotectant like trehalose was also evaluated. Methods: Blood from three healthy donors was collected to obtain eye drops by PRGF technology. The resultant eye drops were divided in four groups: PRGF, freeze-dried PRGF (PRGF lyo), and PRGF lyophilized mixed with 2,5% trehalose (PRGF lyo+2.5T) or 5% trehalose (PRGF lyof+5T). Chemical and biological characteristics were evaluated. Photorefractive keratectomy was performed on C57BL/6 mice which were divided in three treatment groups: control, PRGF, and PRGF lyo. Corneal wound healing and haze formation were evaluated macroscopically. Eyes were collected at 1, 2, 3, and 7 days after surgery, and were processed for histologic studies. Results: The pH values of PRGF samples increased significantly after the lyophilization process. Osmolarity levels increased significantly in PRGF samples mixed with trehalose in comparison with PRGF samples without protectants. The freeze drying process maintained growth factors levels as well as the biological properties of PRGF eye drops even without the use of lyoprotectants. PRGF lyo treatment significantly decreased the re-epithelialization time and haze formation in photorefractive keratectomy-treated corneas regarding PRGF and control groups. Furthermore, the PRGF lyo group significantly decreased the number of smooth muscle actin-positive cells in comparison with the control group at each time of the study and at days 2 and 3 in the PRGF group. Conclusions: The freeze drying process preserves the protein and growth factor content as well as the biological properties of PRGF eye drops, even without the use of protectants. Freeze-dried PRGF eye drops accelerate corneal tissue regeneration after photorefractive keratectomy in comparison with the control group. Translational Relevance: Our study shows the feasibility to preserve the biological capability of PRGF eye drops as freeze-dried formulation, avoiding the addition of protectants. Resumen (Foreign Language Abstract): Objetivo: Investigar si el colirio de plasma rico en factores de crecimiento (PRGF) mantiene su potencial biológico después de un proceso de liofilización. También se evaluó la adición de un lioprotector como la trehalosa. Métodos: Se recogió sangre de tres donantes sanos para obtener colirio mediante la tecnología PRGF. El colirio resultante se dividió en cuatro grupos: PRGF, PRGF liofilizado (PRGF lyo) y PRGF liofilizado mezclado con trehalosa al 2,5% (PRGF lyo + 2.5T) o trehalosa al 5% (PRGF lyof + 5T). Se evaluaron las características químicas y biológicas de cada uno de los colirios. Se realizó una queratectomía fotorrefractiva (PRK) en ratones C57BL/6 que se dividieron en tres grupos de tratamiento: Control, PRGF y PRGF lyo. La curación de la herida corneal y la formación de "haze"se evaluaron macroscópicamente.

show abstract

Autologous Plasma Rich in Growth Factors Eyedrops in Refractory Cases of Ocular Surface Disorders

Cited by 48 publications

References 26 publications

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

WITHDRAWN: Treatment of Noninfectious Corneal Disorders With Plasma Rich in Growth Factors and ReGenerating Agent Matrix

Plasma rich in growth factors eye drops to treat secondary ocular surface disorders in patients with glaucoma

Development and Optimization of Freeze-Dried Eye Drops Derived From Plasma Rich in Growth Factors Technology

Contact Info

Product

Resources

About